VSGN Vasogen Inc. featured news, full reports, and detailed charts
Vasogen Inc. (VSGN) Wrap Up:
We are focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The recently completed international 2,408-patient double-blind, placebo-controlled ACCLAIM trial assessed the impact of our lead product, Celacade, on reducing the risk of mortality and morbidity in patients with chronic heart failure ("HF"). On June 26, 2006, we announced the initial results from the 2,408-patient ACCLAIM trial. While the ACCLAIM study did not reach the primary endpoint of significantly reducing the risk of death or cardiovascular hospitalization in the total patient population, this endpoint was met for a pre-specified subgroup of 689 patients with New York Heart Association ("NYHA") Class II chronic HF. Additional results for the ACCLAIM study were presented at the World Congress of Cardiology 2006, held in Barcelona, Spain, at the 10th Annual Scientific Meeting of the Heart Failure Society of America in Seattle, Washington, and at the 2006 Canadian Cardiovascular Congress held in Vancouver, British Columbia. ... More..."http://secfilings.nasdaq.com/edgar_conv_html/2007/02/01/0000950142-07-000333.html#FIS_COMPANY_INFORMATION"
More Recent News About Vasogen Inc.
More news for VSGN
Vasogen Announces Third Quarter 2009 Results
MISSISSAUGA, ON, Oct. 15 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN - News; TSX:VAS - News) today reported the results of operations for the three and nine months ended August 31, 2009. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted. At August 31, 2009, our cash and cash equivalents totaled $4.8 million, compared with $5.8 million at May 31, 2009. Our net cash used in operating activities for the three months ended August 31, 2009, was $1.0 million and included the payment of $0.4 million for fees mainly related to our ongoing strategic review and $0.3 million for restructuring costs.The net loss for the third quarter of 2009 was $1.2 million, or $0.05 per common share, compared with a net loss of $2.6 million, or $0.12 per common share for the same period in 2008. The $1.2 million loss for the three months ended August 31, 2009 included a charge for fees of $0.7 million mainly related to our ongoing strategic review, which included the cost of the fairness opinion rendered by JMP Securities LLC in connection with the proposed business combination with IntelliPharmaCeutics.We incurred a net loss for the nine months ended August 31, 2009 of $4.5 millio...Click here to read the whole Article (external link)
VASOGEN INC Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Vasogen Inc. and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger
MISSISSAUGA, ON, Oct. 19 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN - News; TSX:VAS - News) and IntelliPharmaCeutics Ltd. ("IPC") are pleased to announce that shareholders of each company have approved the plan of arrangement and merger pursuant to which Vasogen will combine with IPC to continue as a publicly-traded entity to be called IntelliPharmaCeutics International Inc. IPC is a privately-held specialty pharmaceutical company that is focused on developing and manufacturing new and generic controlled-release pharmaceutical products using its broadly applicable, proprietary delivery technologies. Separately, Vasogen's shareholders also approved the plan of arrangement with Cervus LP (TSXV:CVL.UN), an Alberta based limited partnership, that will reorganize Vasogen prior to completion of the transaction with IPC and which will provide gross proceeds to Vasogen of approximately Cdn$7.5 million in non-dilutive capital. Vasogen and IPC have been advised that the securityholders of Cervus and of Cervus GP Ltd., the general partner of Cervus, respectively, have also approved the plan of arrangement.Various other customary closing conditions remain to be satisfied, including obtaining a final order ...Click here to read the whole Article (external link)
Would you like to leave a comment about Vasogen Inc. VSGN
Find out what social network information about Vasogen Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Vasogen Inc. there is more great information available at Realpennies.com